21
Apr
Lycotec quest to target the deadliest of crystals
Lycotec Ltd, a biotech company based in Cambridge UK, is raising funds to undertake a phase II clinical trial which would target cholesterol crystals. These crystals are one of the main causes of the rupture of atherosclerotic plaques. After breaking the cap of a vulnerable plaque, the crystals protrude into the lumen of coronary or […]
Read more
Categories
Recent posts
-
Lycotec presents at the American Heart Association’s Scientific Sessions4th November 2021
-
Lycotec CEO, Dr Ivan Petyaev to attend The Future Food-Tech Summit9th October 2019
Newsletter
Subscribe to our weekly newsletter now. Enter your email and name and click subscribe
Recent Tweets
-
Fonts, typefaces, characters – there's a lot to learn when it comes to typography... To get you started, we've put… https://t.co/1PjLFWRyb1
2 days ago -
@CorinaObertas Congratulations! 💚🎉🙌
2 days ago -
Save the Bees 🐝🐝! @Envato is sponsoring #Beehives and going carbon neutral ♻️. Here's how we are helping Backyard… https://t.co/1GTk8pI92t
3 days ago
Recent Comments